Drug intelligence / Profile preview

QL425

Development stage: Preclinical
Lead developer: QLSF Biotherapeutics
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Intravenous, Subcutaneous

Overview

QL425 is a preclinical-stage T-cell-targeted cytokine fusion protein being developed by QLSF Biotherapeutics for the treatment of cancer. Designed for 'inflamed' tumors—where T cells are abundant but inactive or exhausted—QL425 aims to reactivate and invigorate these T cells within the tumor microenvironment. The specific cytokine, target, and biological mechanism of action have not been publicly disclosed.

Beyond the preview

Go deeper on QL425.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QL425.

Explore the full profile